Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with locoregionally advanced, EBV-positive nasopharyngeal cancer (a specific type of head and neck cancer) at certain stages, with no spread to distant parts of the body (confirm with trial site for exact staging details)
• People who have not previously received any treatment for this type of cancer
• People with a life expectancy of at least 3 months
• Women who could become pregnant, and sexually active male participants, who agree to use effective birth control during treatment and for 4 months after the last dose
• People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning they are able to carry out at least some daily activities)
• People aged 18 years or older
• People whose recent blood test results show the bone marrow is producing enough blood cells (specific counts will be checked within 21 days before treatment starts)
• People whose recent blood tests show the liver is functioning adequately (checked within 21 days before treatment starts)
• People whose recent blood tests show the kidneys are functioning adequately (checked within 21 days before treatment starts)
• Women who could become pregnant must have a negative pregnancy blood test within 14 days before treatment starts
• People who are able to understand the study and are willing to sign the official consent form personally

Who may not be able to join:

• People who have previously had systemic (whole-body) anti-cancer treatment for this type of cancer
• People who have previously had radiation therapy to the head and neck area that would overlap with the radiation fields used in this trial
• People currently receiving any other anti-cancer treatment, whether standard, alternative, or experimental
• People with a known history of allergic reactions to any of the medications used in this study
• People with an autoimmune disease or who have had an organ transplant, where the treating doctor judges this would increase the risks of the immunotherapy used in this trial
• People who are pregnant or breastfeeding
• People with serious, active health conditions, including: a major medical or psychiatric illness that the investigator believes would interfere with completing treatment; unstable chest pain or uncontrolled heart failure in the past 6 months; a heart attack in the last 6 months; a current serious bacterial or fungal infection requiring antibiotics given through a drip (note: people on antibiotics whose infection is considered well-controlled may still be eligible); a serious lung condition flare-up or breathing illness requiring hospitalisation within 30 days before treatment starts
• People with AIDS as defined by current medical guidelines (HIV testing is not required to apply, but people with AIDS are excluded because the treatments may significantly affect the immune system)
• People with significant hearing loss that is nerve-related in nature, requiring a hearing aid or other intervention that noticeably affects daily life (hearing loss caused by the tumour itself may be acceptable — confirm with trial site)
• People with moderate or severe nerve-related numbness or tingling in the hands or feet (grade 2 or higher peripheral neuropathy)

Important: Always verify eligibility with the trial site directly before applying.